Discover
CYTK
Cytokinetics, Incorporated
76.45
1 x 75.80
1 x 79.00
bid
ask
-
1.04
1.34%
1 @ 04:00 PM
77.52 +1.07 (1.40%)
| Ytd | 20.32% | |
| 1y | 130.06% |
76.30
day range
78.95
33.17
52 week range
88.31
| Open | 78.65 | Prev Close | 77.49 | Low | 76.30 | High | 78.95 | Mkt Cap | 9.51B |
| Vol | 1.24M | Avg Vol | 2.10M | EPS | -6.21 | P/E | -12.31 | Forward P/E | -17.27 |
| Beta | 0.38 | Short Ratio | 6.62 | Inst. Own | 120.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-05 | 50-d Avg | 78.69 | 200-d Avg | 68.49 | 1yr Est | 108.85 |
| Income Statement | |||
| Total Revenue | 28.62M | ||
| Revenues (USD) | 28.62M | ||
| Cost of Revenue | 5.59M | ||
| Gross Profit | 23.03M | ||
| Operating Expenses | 202.20M | ||
| Research and Development Expense | 97.81M | ||
| Selling, General and Administrative Expense | 104.40M | ||
| Operating Income | -179.17M | ||
| Interest Expense | 14.65M | ||
| Net Income | -198.76M | ||
| Net Income Common Stock | -198.76M | ||
| Net Income Common Stock (USD) | -198.76M | ||
| Consolidated Income | -198.76M | ||
| Earnings per Basic Share | -1.50 | ||
| Earnings per Basic Share (USD) | -1.50 | ||
| Earnings per Diluted Share | -1.50 | ||
| Earning Before Interest & Taxes (EBIT) | -184.11M | ||
| Earning Before Interest & Taxes (USD) | -184.11M | ||
| Weighted Average Shares | 132.09M | ||
| Weighted Average Shares Diluted | 132.09M | ||
| Balance Sheet | |||
| Cash and Equivalents | 255.27M | ||
| Cash and Equivalents (USD) | 255.27M | ||
| Investments | 1.45B | ||
| Investments Current | 910.42M | ||
| Investments Non-Current | 538.32M | ||
| Trade and Non-Trade Receivables | 24.43M | ||
| Current Assets | 1.21B | ||
| Property, Plant & Equipment Net | 151.81M | ||
| Total Assets | 1.92B | ||
| Debt Current | 48.40M | ||
| Total Debt | 1.27B | ||
| Current Liabilities | 181.43M | ||
| Debt Non-Current | 1.22B | ||
| Total Liabilities | 2.10B | ||
| Accumulated Retained Earnings (Deficit) | -3.89B | ||
| Accumulated Other Comprehensive Income | -3.83M | ||
| Shareholders Equity | -173.49M | ||
| Shareholders Equity (USD) | -173.49M | ||
| Assets Non-Current | 716.06M | ||
| Total Debt (USD) | 1.27B | ||
| Deferred Revenue | 1.65M | ||
| Inventory | 6.91M | ||
| Liabilities Non-Current | 1.92B | ||
| Trade and Non-Trade Payables | 20.51M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 3.63M | ||
| Net Cash Flow from Financing | 792.86M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 125.42M | ||
| Capital Expenditure | -4.33M | ||
| Issuance (Purchase) of Equity Shares | 798.15M | ||
| Issuance (Repayment) of Debt Securities | -3.81M | ||
| Net Cash Flow from Investing | -507.00M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -502.66M | ||
| Net Cash Flow from Operations | -159.84M | ||
| Effect of Exchange Rate Changes on Cash | -595.00K | ||
| Share Based Compensation | 35.71M | ||